Erudio Healtherudio.com
Sponsor
ArriVent BioPharma trials: what clinicians said in public
HCP commentary reports on 2 clinical trials sponsored by ArriVent BioPharma: ALPACCA and FURVENT. Each covers what clinicians said in public about one trial, on podcasts, videos and posts, every statement linked to its source. Below them, 1 more trial with public commentary and no report yet.
Listed by lead sponsor as registered on ClinicalTrials.gov (ArriVent BioPharma, Inc.). A trial led by a partner or a research group is on that sponsor's page. Only trials with public clinician commentary found are listed, not every trial the sponsor runs.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| FURVENT NCT05607550 · ArriVent BioPharma, Inc. | advanced NSCLC with EGFR exon 20 insertion mutations | Phase 3 | 107 | 53 | Focused | Nov 2, 2026 | Preview |
| ALPACCA NCT07185997 · ArriVent BioPharma, Inc. | first-line locally advanced or metastatic EGFR PACC NSCLC | Phase 3 | 13 | 5 | Focused | Nov 1, 2026 | Preview |
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| NCT05364073 NCT05364073 · ArriVent BioPharma, Inc. FocusedView → | advanced or metastatic NSCLC with EGFR/HER2 mutations | Phase 1 | Focused | View | |||